Charles River Laboratories International (CRL) to Release Earnings on Thursday

Charles River Laboratories International (NYSE:CRL) will post its quarterly earnings results before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of $2.05 per share for the quarter. Charles River Laboratories International has set its FY24 guidance at $10.90-11.40 EPS and its FY 2024 guidance at 10.900-11.400 EPS.Investors that wish to register for the company’s conference call can do so using this link.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.39 by $0.07. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The company’s revenue was down 7.9% on a year-over-year basis. During the same quarter last year, the company earned $2.98 earnings per share. On average, analysts expect Charles River Laboratories International to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $236.30 on Wednesday. Charles River Laboratories International has a 12 month low of $161.65 and a 12 month high of $275.00. The stock has a market capitalization of $12.17 billion, a P/E ratio of 25.66, a PEG ratio of 1.83 and a beta of 1.44. The company has a current ratio of 1.52, a quick ratio of 1.16 and a debt-to-equity ratio of 0.73. The firm’s 50 day moving average is $251.61 and its 200 day moving average is $225.17.

Analysts Set New Price Targets

CRL has been the subject of a number of analyst reports. Argus raised their price target on Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, March 18th. JPMorgan Chase & Co. upped their price target on Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Guggenheim lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Evercore ISI upped their target price on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. Finally, TheStreet raised shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $253.23.

Insider Buying and Selling

In other news, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the transaction, the executive vice president now directly owns 2,596 shares in the company, valued at approximately $626,155.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Shannon M. Parisotto sold 5,882 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares in the company, valued at approximately $626,155.20. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP William D. Barbo sold 4,050 shares of the stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the transaction, the vice president now directly owns 22,879 shares in the company, valued at approximately $5,685,431.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 14,932 shares of company stock worth $3,693,663. Corporate insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).